OTC · LGNDZ

Ligand Pharmaceuticals, Inc.

Healthcare · Medical - Pharmaceuticals

$0.00

Up+$0.00 (+18.75%)

Updated Aug 15, 2026, 6:39 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 157.46K
P/E ratio: 99
Dividend yield: 0.00%
52-week range: $0.00 – $0.02
Volume: 10K
Avg. volume: 56.76K

Price performance

LGNDZ price history

1M range · 2 trading sessions · Daily adjusted prices

Last close: $0.00
Period change: +18.75%
Period low: $0.00
Period high: $0.00

Daily close

View OHLC price history

LGNDZ OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Aug 7, 2026	$0.0016	$0.0019	$0.0016	$0.0019	10K
Jul 23, 2026	$0.0016	$0.0016	$0.0016	$0.0016	100

Latest LGNDZ news

The latest Smart Investors Daily articles mentioning LGNDZ.

analystJul 8, 2026

Stifel Reiterates Buy Rating on Ligand Pharmaceuticals, Inc. (LGNDZ)

Latest LGNDZ news

The latest Smart Investors Daily articles mentioning LGNDZ.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

LGNDZ research

Overview

Company profile and research snapshot.

Company profile

LIGAND PHARMS INC CVR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: Buy
Average target: —
Implied upside: —
Analysts: 13

LGNDZ recent ratings
Date	Firm	Rating	Target
Aug 14, 2026	Leerink Partners	Outperform	—
Aug 7, 2026	RBC Capital	Outperform	—
Aug 6, 2026	HC Wainwright & Co.	Buy	—
Aug 3, 2026	Oppenheimer	Outperform	—
Jul 21, 2026	Citigroup	Buy	—

Open full forecast

News briefing

No generated briefing is available yet.

SeekingAlpha · Apr 27, 2026